1. European Urology Oncology
Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy 
Karl Patterson, Vimalanand Prabhu, Ruifeng Xu, Haojie Li, Yang Meng, Natalie Zarabi, Yichen Zhong, Rachael Batteson, James Pellissier, Stephen Keefe, Petros Grivas, Ronald de Wit 
European Urology Oncology 
DOI: /j.euo
Copyright © 2018 Merck Sharp & Dohme Corp and The Authors Terms and Conditions

2. Fig. 1
Model structure.
European Urology Oncology DOI: ( /j.euo )
Copyright © 2018 Merck Sharp & Dohme Corp and The Authors Terms and Conditions

3. Fig. 2
Kaplan-Meier (KM) and fitted survival curves. SOC=standard of care (gemcitabine plus carboplatin).
European Urology Oncology DOI: ( /j.euo )
Copyright © 2018 Merck Sharp & Dohme Corp and The Authors Terms and Conditions

4. Fig. 3
One-way sensitivity analysis for pembrolizumab versus standard of care (SOC). AE=adverse event; ICER=incremental cost-effectiveness ratio; KN052=KEYNOTE-052; Lnormal=log-normal; OS=overall survival; PFS=progression-free survival.
European Urology Oncology DOI: ( /j.euo )
Copyright © 2018 Merck Sharp & Dohme Corp and The Authors Terms and Conditions

5. Fig. 4
Cost-effectiveness acceptability curve. SOC=standard of care (carboplatin plus gemcitabine).
European Urology Oncology DOI: ( /j.euo )
Copyright © 2018 Merck Sharp & Dohme Corp and The Authors Terms and Conditions